SLC2A1 and neoplasm: Boosting tumour cell glycolysis by overexpressing MYC, glycolytic enzymes or GLUT-1 increased tumour progression, while suppression of glycolysis by checkpoint blockade therapy restored T cell responses and resulted in tumour regression [73].